Fresh funding backs the first human trial of a therapy designed to make older, damaged cells act younger again.
In a world where age is the biggest risk factor for disease, Boston-based biotech Life Biosciences is pushing something that sounds almost like fiction: what if cells could be nudged back to a younger, healthier state? The company has announced an $80 million Series D raise to advance this vision, funding the first human trial of its “cell reset” therapy, ER-100, while expanding its broader platform for treating age-related conditions.
The raise is a vote of confidence. Investors are increasingly willing to back companies that aim to go beyond treating symptoms and instead address the underlying biology of aging itself. For Life Bio, this means helping damaged cells regain youthful function, potentially slowing, preventing or even reversing multiple diseases of aging.
Why the eye became the proving ground
ER-100 is being tested in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), conditions that can cause permanent vision loss. At first glance, the eye might seem like a niche focus, but it’s actually the perfect proving ground for longevity therapies.
The reason: in these conditions, the nerve cells that connect the eye to the brain are damaged. Unlike other cells in the body, these neurons do not naturally regenerate. Current treatments mostly manage symptoms rather than repair the underlying damage. ER-100’s approach is different; it aims to help these cells recover function, giving them a chance to “remember” how to act like younger, healthier cells.
Think of it like updating an old smartphone. You can’t make it brand-new again, but with the right software tweaks, it can regain much of its original speed and responsiveness. That’s the hope here: partial cellular reprogramming without erasing what makes each cell unique.
Earlier this year, Life Bio hit a major milestone. The FDA cleared its investigational new drug (IND) application for ER-100, making it the first therapy of its kind using partial epigenetic reprogramming to enter human trials. Partial epigenetic reprogramming may sound like a mouthful, but in simple terms, it’s a way of nudging cells to “forget” some of the damage that comes with aging, without turning them into something else entirely.
It’s a subtle reset, a biological reminder of what youth looks like at the cellular level. And while it’s early days, getting to clinical trials is a critical step. For the longevity field, this is the moment ideas meet reality, moving from mouse models and lab dishes to human patients.
“We are encouraged by the strong participation in this financing, which reflects the growing interest in our platform and the opportunity we have to reverse multiple diseases of aging,” said Jerry McLaughlin, CEO of Life Biosciences. “This support enables us to advance our lead program, ER-100, through key clinical milestones while continuing the expansion of our pipeline, positioning Life Bio to deliver disease-modifying solutions for patients.”
Beyond one drug: the promise of a platform
ER-100 is the headline, but Life Bio’s ambitions extend much further. Its Partial Epigenetic Reprogramming (PER) platform is designed to restore older or injured cells across different organs and systems. By addressing aging at its root, the company is betting that many chronic diseases – heart disease, neurodegeneration, vision loss – share a common origin: the slow decline of cellular function over time [1].
This is what makes the raise exciting. Investors aren’t just funding a single therapy; they’re backing a new way to think about aging. If PER works, it could be a toolkit for improving health span, helping people stay active, independent and healthy for longer.
Now, onto longevity’s real test…of course, the path from lab to clinic is never straightforward. Phase 1 trials are designed primarily to assess safety and tolerability, and there are no guarantees. But in the world of longevity biotech, taking a bold first step is everything.
Life Bio’s $80 million raise isn’t a guarantee of success. It’s a bet on possibility, on the idea that aging can be addressed at its source, rather than just treated at its symptoms. Moreover, if even a portion of that potential is realized, it could reshape how we think about growing older.
